Home › Research › Treatments
Is Australia ready for the rollout of amyloid‐targeting therapies for Alzheimer disease? Results from a national survey characterising current infrastructure capability, workforce and training needs of memory and cognition clinics
Johannes C. Michaelian, Christopher C. Rowe, Susan E Kurrle, Constance Dimity Pond, Michael Woodward, Sharon Linda Naismith. Internal Medicine Journal, 2025-02-06
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Thirty medical specialists (geriatricians, n = 23; psychiatrists, n = 4; neurologists, n = 3) from 30 different clinics participated (public, 76.7%; private, 23.3%), including from metropolitan (73.3%), regional (20.0%) and rural (6.7%) areas. On average, clinics reported assessing 5.4 (SD = 3.2) new patients per week, of which 2.4 (range: 0-5) were considered to have mild cognitive impairment (MCI). Only 40% of clinics use biomarkers to assess whether patients with MCI have AD, and 45% have intravenous infusion capability. While the majority of clinicians were confident in their knowledge of mAbs, only 33% felt confident in using these. Identified impediments to clinical implementation included (i) lack of real-world experience, (ii) lack of current Models of Care and appropriate use guidelines, (iii) current clinic set-up and (iv) information about safety. Australia's health system preparedness for amyloid-targeting mAb therapies will require further investment in infrastructure, equity of access, clinician training and support. Long wait times already impact access to clinics, and with the forecast rise in MCI and dementia cases, services will need to be expanded, and appropriate Models of Care and clear and efficient inter-sector health pathways will be needed to prepare for the use of mAbs.
What this study adds
Evidence grade: Low
This is a cross-sectional study of 23 participants. A survey of Australian memory clinics found that only 40% use biomarkers to assess whether patients with mild cognitive impairment have Alzheimer disease, and only 45% have intravenous infusion capability. Reported effect size: 76.7%; 23.3%; 73.3%.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Michaelian, J. C., Rowe, C. C., Kurrle, S. E., Pond, C. D., Woodward, M., & Naismith, S. L. (2025). Is Australia ready for the rollout of amyloid‐targeting therapies for Alzheimer disease? Results from a national survey characterising current infrastructure capability, workforce and training needs of memory and cognition clinics. Internal Medicine Journal. https://doi.org/10.1111/imj.16637
Vancouver
Michaelian JC, Rowe CC, Kurrle SE, Pond CD, Woodward M, Naismith SL. Is Australia ready for the rollout of amyloid‐targeting therapies for Alzheimer disease? Results from a national survey characterising current infrastructure capability, workforce and training needs of memory and cognition clinics. Internal Medicine Journal. 2025. doi:10.1111/imj.16637. PMID: 39912236.
BibTeX
@article{michaelian2025-39912236,
author = {Michaelian, Johannes C. and Rowe, Christopher C. and Kurrle, Susan E and Pond, Constance Dimity and Woodward, Michael and Naismith, Sharon Linda},
title = {{Is Australia ready for the rollout of amyloid‐targeting therapies for Alzheimer disease? Results from a national survey characterising current infrastructure capability, workforce and training needs of memory and cognition clinics}},
journal = {Internal Medicine Journal},
year = {2025},
doi = {10.1111/imj.16637},
pmid = {39912236},
url = {https://doi.org/10.1111/imj.16637}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Thirty medical specialists (geriatricians, n = 23; psychiatrists, n = 4; neurologists, n = 3) from 30 different clinics participated (public, 76.7%; private, 23.3%), including from metropolitan (73.3%), regional (20.0%) and rural (6.7%) areas.
- On average, clinics reported assessing 5.4 (SD = 3.2) new patients per week, of which 2.4 (range: 0-5) were considered to have mild cognitive impairment (MCI).
- Only 40% of clinics use biomarkers to assess whether patients with MCI have AD, and 45% have intravenous infusion capability.
- While the majority of clinicians were confident in their knowledge of mAbs, only 33% felt confident in using these.
- Identified impediments to clinical implementation included (i) lack of real-world experience, (ii) lack of current Models of Care and appropriate use guidelines, (iii) current clinic set-up and (iv) information about safety.
Why it matters
A survey of Australian memory clinics found that only 40% use biomarkers to assess whether patients with mild cognitive impairment have Alzheimer disease, and only 45% have intravenous infusion capability. Preparing for amyloid-targeting therapies will require more investment in infrastructure, equity of access, clinician training and support.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Study designcross-sectional
- Participants23
- Effect size76.7%; 23.3%; 73.3%
- Evidence strengthLow
How this study scored 51/100
Published in a peer-reviewed journal, and it is a snapshot of people at one point in time. Scored zero for randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Internal Medicine Journal) |
| Journal's citation record | 1 / 4 | Internal Medicine Journal: journal h-index 99 (OpenAlex, 2026-10-29) |
| Study design | 4 / 12 | A snapshot of people at one point in time |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 1 / 4 | 23 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 6 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 2.0 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 3 / 6 | Cited 3.2× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 1 other studies in this library |
| Still being cited | 1 / 4 | Cited 6 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Sharon Linda Naismith: h-index 78 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | The University of Sydney: institution h-index 1,466 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 5 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 39912236) |
| Free to read | 2 / 2 | Free to read |
| Total | 51 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1111/imj.16637
- PubMed: 39912236
- Original source →
- Free full text: Internal Medicine Journal →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
1 study in the alzhub library lists this one in its references.
Related studies in Treatments from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.